gemfibrozil has been researched along with ethanolamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Dhaneshwar, SS; Rai, H | 1 |
2 other study(ies) available for gemfibrozil and ethanolamine
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study.
Topics: Amides; Animals; Cholesterol, HDL; Disease Models, Animal; Ethanolamine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Molecular Docking Simulation; Octoxynol; PPAR alpha; Rats; Rats, Wistar | 2015 |